Skip to main content

Table 1 Risk class and probability of hospitalization

From: Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants

 

Prophylaxis

Non prophylaxis

Probability of occurrence

33–35 wks

< 33 wks

BPD

33–35 wks

< 33 wks

BPD

Risk class

      

- patient rate

11.0%

70.0%

19.0%

11.0%

70.0%

19.0%

Probability of hospitalization

      

- ordinary ward

1.5%

2.0%

5.6%

9.8%

10.3%

18.4%

- Intensive therapy unit

1.3%

1.3%

1.3%

3.0%

3.0%

3.0%

  1. From: Ravasio R et al. [15]